Education
About Us
Working with TipRanks
Follow Us
NeoGenomics (NEO)
NASDAQ:NEO
NEO Stock Chart & Stats
$10.05
$0.52(2.83%)
At close: 4:00 PM EST
$10.05
$0.52(2.83%)
Day’s Range― - ―
52-Week Range$4.72 - $19.12
Previous CloseN/A
Volume108.49K
Average Volume (3M)3.76M
Market Cap
$1.33B
Enterprise Value$1.18B
Total Cash (Recent Filing)$163.69M
Total Debt (Recent Filing)$411.76M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Oct 28, 2025EPS Estimate
0.02Last Dividend Ex-Date
Dec 17, 2020Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding129,178,620
10 Day Avg. Volume5,911,937
30 Day Avg. Volume3,760,153
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue1.72
Enterprise Value/Gross Profit3.91
Enterprise Value/Ebitda-24.41
Forecast
1Y Price Target
$11.33Price Target Upside12.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
Bulls Say, Bears Say
Bulls Say
Legal VictoryNEO announced that it had won a summary judgment in its RaDaR patent infringement case with Natera.
Market ExpansionRaDaR ST could become a significant growth driver considering the large multi-billion dollar total available market for MRD testing.
Product InnovationManagement stressed the strength of its community channel enabling high impact new product introductions.
Bears Say
Delayed Product LaunchThe major driver of the guidance cut was a delayed launch of Pantracer LBx.
Macroeconomic PressureThe volatile macro issues around biopharma (tariffs, NIH spending, drug pricing) are not likely to abate anytime soon.
Revenue GuidanceNEO shares are down on what turned out to be a larger than expected guide cut to FY25.
NeoGenomics News
NEO FAQ
What was NeoGenomics’s price range in the past 12 months?
NeoGenomics lowest stock price was $4.72 and its highest was $19.11 in the past 12 months.
What is NeoGenomics’s market cap?
NeoGenomics’s market cap is $1.33B.
When is NeoGenomics’s upcoming earnings report date?
NeoGenomics’s upcoming earnings report date is Oct 28, 2025 which is in 9 days.
How were NeoGenomics’s earnings last quarter?
NeoGenomics released its earnings results on Jul 29, 2025. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of $0.023 by $0.007.
Is NeoGenomics overvalued?
According to Wall Street analysts NeoGenomics’s price is currently Undervalued.
Does NeoGenomics pay dividends?
NeoGenomics pays a Notavailable dividend of $0.4 which represents an annual dividend yield of N/A. See more information on NeoGenomics dividends here
What is NeoGenomics’s EPS estimate?
NeoGenomics’s EPS estimate is 0.02.
How many shares outstanding does NeoGenomics have?
NeoGenomics has 129,178,620 shares outstanding.
What happened to NeoGenomics’s price movement after its last earnings report?
NeoGenomics reported an EPS of $0.03 in its last earnings report, beating expectations of $0.023. Following the earnings report the stock price went down -18.731%.
Which hedge fund is a major shareholder of NeoGenomics?
Currently, no hedge funds are holding shares in NEO
NeoGenomics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.33 (12.74% Upside)
$11.33 (12.74% Upside)
Blogger Sentiment
Neutral
NEO Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 2.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $212.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 0.6%
Last 30 Days ▲ 0.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.66%
12-Months-Change
Fundamentals
Return on Equity
-11.76%
Trailing 12-Months
Asset Growth
-15.17%
Trailing 12-Months
Company Description
NeoGenomics
NeoGenomics, Inc. is a leading provider of cancer-focused genetic testing and diagnostic services. The company operates primarily in the healthcare sector, specializing in advanced genomic testing for oncology. NeoGenomics offers a comprehensive range of services, including molecular testing, hematopathology, and clinical trial services, aimed at improving cancer patient outcomes through precise and personalized treatment options.
NEO Company Deck
NEO Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook. While the clinical segment showed robust growth and operational achievements, significant challenges in the nonclinical and pharma segments led to a downward revision of the full-year financial guidance. The company is taking steps to address these issues, but the immediate future appears cautious.View all NEO earnings summariesNEO Stock 12 Month Forecast
Average Price Target
$11.33
▲(12.74% Upside)
Technical Analysis
Ownership Overview
1.23% Insiders
30.08% Mutual Funds
0.16% Other Institutional Investors
44.02% Public Companies and
Individual Investors